|Abstracts cover latest developments in the Company’s HIV/AIDS Clinical Trials for Salvage Therapy and Strategic Treatment Intervention (STI)
Philadelphia, PA, Tuesday, June 18, 2002: Hemispherx Biopharma Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that the Committee of the XIV International Aids Conference to be held in Barcelona, Spain from July 7 to 12, 2002 has confirmed the acceptance of the Company’s two Late Breaker Abstracts.
Recently the Company had filed two abstracts for submission to be presented as Late Breakers at the Aids 2002 Barcelona Conference, which is the most important Aids conference of the year. The percentage of abstracts selected for late breakers depends on the number of submissions but the process for acceptance or rejection is certainly more rigorous than for regular abstracts. Late Breaker Abstracts contain significant data that not have been published or submitted for presentation to any national or international meeting before the XIV International Aids Conference.
Hemispherx Biopharma, Inc is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one experimental Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS).
Dr. William Carter, Chairman and CEO of Hemispherx Biopharma Inc, stated “we are very pleased with this notification of acceptance for both of our abstracts, covering both of our clinical trials in HIV/AIDS. We believe that it validates the importance and significance of the data we have submitted to present at the Conference. The presentations also create the opportunity to compare the duration of the biological effects of our lead product, Ampligen, with those afforded by other drug candidates with new mechanisms of action, such as fusion inhibitors.”
For more information, please visit the Company’s website at www.hemispherx.net.
Hemispherx Biopharma, Inc., Investor Relations (215) 988-1712, Fax: (215) 988-1554
Dianne Will, Investor Relations, (518) 398-6222, Fax: (518) 398-6223
Robert Giordano, MRB Institutional Investors, MRB, (212) 495-0200,
Fax: (212) 495-0746
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.